Administration of HIF-1α inhibitors can block the upregulation of MMP2 and delay the progression of liver cancer, providing further verification of the conclusion that the HIF-1α/MMP2 or HIF-1α/MMP9 signaling pathways are involved in the occurrence and development of liver cancer [87]. Here, HIF1A is linked to liver cancer.